Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03298477 · ClinicalTrials.gov registry record · NA
EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study
A NA study of Abdominal Aortic Aneurysm Without Rupture, sponsored by Endologix.
- Active
- Registry status
- NA
- Development phase
- 98
- Enrollment target
- 20
- Study locations
NCT03298477: Active NA study of Abdominal Aortic Aneurysm Without Rupture, sponsored by Endologix.
NCT03298477 is a NA study of Abdominal Aortic Aneurysm Without Rupture that is active but no longer recruiting, run by Endologix. The registered enrollment target is 98 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03298477, a NA study of Abdominal Aortic Aneurysm Without Rupture, is active but no longer recruiting, sponsored by Endologix.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 98 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System.
Primary Outcome
The primary safety endpoint is defined as the incidence of Major Adverse Events (MAE) at 30 days, defined as the composite of the following All-Cause Mortality; Bowel Ischemia; Myocardial Infarction; Paraplegia; Renal Failure; Respiratory Failure; Stroke; Procedural Blood Loss ≥1,000cc
Conditions Studied
Interventions
- DEVICE Nellix® System
Study Locations (20)
Florida
- Miami Cardiac & Vascular Institute (MCVI) - Miami
- AdventHealth Orlando - Orlando
- Coastal Vascular & Interventional - Pensacola
California
- Regents of the University of California (UCLA) - Los Angeles
- Veterans Medical Research Foundation - San Diego
Illinois
- Christie Clinic - Champaign
- AMITA Health - Elk Grove Village
Ohio
- Cleveland Clinic - Cleveland
- Northeast Ohio Vascular Assoc (NEOVA) - Willoughby
Alabama
- Valley Vascular Consultants - Huntsville
Colorado
- UC Health-Memorial Hospital - Colorado Springs
District of Columbia
- MedStar Health Research Institute - Washington D.C.
Indiana
- St. Vincent Heart Center of Indiana - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2025-08-16 |
| Phase | NA |
What the registry record for NCT03298477 still lists
NCT03298477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Abdominal Aortic Aneurysm Without Rupture appearing as the primary indexed condition, and to 1 intervention - of which Nellix® System is the first listed.
NCT03298477 names 20 study sites across 15 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT03298477 about?
NCT03298477 is a clinical study titled "EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study". Prospective, multicenter, single arm study with consecutive, eligible subject enrollment at each site. All subjects will undergo the Endovascular Aneurysm repair procedure with the Nellix System.
What is the current status of trial NCT03298477?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 98 participants. The study started on 2017-12-01. Estimated completion is 2025-08-16.
What conditions does trial NCT03298477 study?
This clinical trial studies the following conditions: Abdominal Aortic Aneurysm Without Rupture.
What interventions are being tested in trial NCT03298477?
The interventions under investigation include: Nellix® System (DEVICE).
Who is sponsoring clinical trial NCT03298477?
This trial is sponsored by Endologix, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03298477 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03298477's enrollment target sits among peer trials
98 922nd of 2000 higher than 1,078 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI